Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase

R. Schwartz-Albiez¹, H.-H. Heidtmann², D. Wolf¹, V. Schirmacher¹ & G. Moldenhauer¹

¹Institute of Immunology and Genetics, German Cancer Research Center, D-6900 Heidelberg; ²Department of Internal Medicine, Division of Hematology/Oncology, Phillips-University, D-3500 Marburg, Germany.

Summary
This study evaluates the cell surface expression of urokinase-type plasminogen activator (u-PA) and the capacity to bind exogenous urokinase as possible parameters for the distinction of various types of human lung tumours. Twelve different tumour cell lines including four small cell carcinoma, two large cell carcinoma, three squamous cell carcinoma, one adenocarcinoma and two mesothelioma cell lines of lung origin were investigated. Surface expression of endogenous u-PA was determined in a cellular radioimmunoassay (CRIA) using the u-PA-specific monoclonal antibody 98/6. To estimate additional u-PA binding capacity, exogenous two-chain, 54 kDa u-PA was employed in the CRIA. The influence of phorbol ester (PMA) treatment on expression and binding of these molecules was studied. Three different groups of lung tumour cell lines could be distinguished according to their expression of u-PA and u-PA-binding ability: (i) non small cell lung carcinoma (NSCLC) cell lines which express small amounts of u-PA and bound little u-PA. Large cell carcinoma cell lines expressed high amounts of u-PA and bound large amounts of u-PA. In general, expression of u-PA and u-PA binding was enhanced after PMA treatment. (ii) Mesothelioma cell lines did not express u-PA, but were able to bind u-PA. (iii) Small cell carcinoma (SCLC) lines were devoid of surface-expressed u-PA and could not bind u-PA, both under untreated and PMA-treated conditions. It could thus be demonstrated that these three groups of lung tumour cell lines differ in their ability to express u-PA and to bind external u-PA. This may reflect the different in vivo growth behaviour and origin of the respective tumour groups.

Based on characteristic histological structures, human lung tumours can be classified into two major groups: NSCLC (squamous cell carcinoma, adenocarcinoma, large cell carcinoma) and SCLC. SCLC can be distinguished from NSCLC by their clinical behaviour, the occurrence of metastases at very early stages of tumour development and certain serological parameters (Gazdar et al., 1981; World Health Organisation, 1982). The biological mechanisms underlying the different metastatic behaviour of these tumour groups are poorly understood.

Since several studies suggested a contribution of plasminogen activators (PA) in tumour invasion and in the formation of distant metastases (Dana et al., 1986; Ossowski & Reich, 1983), we investigated the PA-system in human lung tumour lines in order to better understand the biological basis of these malignancies and to use this enzyme system as possible means to differentiate human lung tumours.

PA-mediated proteolysis may cause degradation of structural constituents of the extracellular matrix (ECM) which may result in a facilitated intra- and extravasation of tumour cells during metastasis formation.

For a more comprehensive evaluation of the relationship between tumour malignancy and PA activity, other components of this enzyme system as, for instance, plasminogen activator inhibitors (PAI) (Cwikel et al., 1984; Eaton & Baker, 1983; Genton et al., 1987) as well as the micro-environment have to be considered. For instance, growth factors like epidermal growth factor (EGF) and transforming growth factor-β (TGF-β) are known to regulate synthesis and secretion of both proteolytic and inhibitory components of the PA system (Keski-Oja et al., 1988; Lee & Weinstein, 1978). In a previous study we analysed both PA and PAI in human lung tumour lines of different origin (Heidtmann et al., 1989). We found that cell lines of NSCLC origin produced and secreted PA of u-PA and t-PA type and PAI in various amounts and combinations. Strikingly, cell lines of SCLC and mesothelioma origin were not able to produce any protein of the PA system. NSCLC cell lines generally showed increased PA activity when treated with EGF and reduced PA activity and enhanced formation of PA/PAI-complexes when treated with TGF-β. SCLC cell lines did not respond to this growth factor. 

PA may not only be effective in tumour-associated degradation processes by a secreted but also by a cell surface-bound form. Receptors for u-PA have been described for several cell types, as for instance for monocytes and the monocytic cell line U937 (Plow et al., 1986; Stopelli et al., 1985; Vassalli et al., 1985), the foetal lung fibroblast cell line GM 1380 (Plow et al., 1986), and the human lung tumour cell line A431 (Stopelli et al., 1986). Recently, a 55 kDa glycoprotein was characterised as an u-PA receptor in cloning and transfectant studies (Roldan et al., 1990). It may well be that tumour cells synthesise little or no u-PA, but may have unoccupied u-PA binding sites which enable them to use external u-PA for degradation processes.

While the autocrine binding of biosynthetic pro-u-PA to the u-PA receptor is well established (Stopelli et al., 1986), binding mechanisms of exogenous u-PA to epithelial cells require closer investigation. For example, several studies indicate an involvement of surface-located proteinase inhibitors, such as PAI-1 (Cubellis et al., 1990) and Protease-Nexin (Baker et al., 1980), in the complexation and processing of u-PA. In a first attempt to study these questions in human lung tumours, we determined the presence of cell surface-expressed u-PA and the capacity to bind exogenous u-PA on human lung tumour lines of NSCLC, SCLC and mesothelioma origin. We also applied PMA in our investigations, since it has been shown to be a potent stimulator of the PA system in various cell types (Eaton & Baker, 1983; Heidtmann et al., 1989; Lee & Weinstein, 1978). By measuring these parameters, three groups of human lung tumour cell lines could be distinguished.

In addition to synthesis and expression of constituents of the PA system, u-PA surface binding may represent a further component to distinguish mesothelioma cell lines from NSCLC and SCLC cell lines. SCLC cell lines, although derived from highly metastatic tumours, were found to be totally deficient of the PA system. The PA system may play a role in the metastatic process of NSCLC and, in an indirect way, mesotheliomas of the lung.

Correspondence: R. Schwartz-Albiez, Institut für Immunologie und Genetik, Deutsches Krebsforschungszentrum Im Neuenheimer Feld 280, D-6900 Heidelberg, Germany.

Received 8 March 1991; and in revised form 2 July 1991.
Materials and methods

Materials

Urokinase 54 kDa (Ukidan, Serono, Freiburg, Germany); urokinase 33 kDa, plasminogen from human plasma, two-chain t-PA from human melanoma cell culture, thrombin, Dowex resin (200—400 mesh size), PMA (Sigma, St. Louis, MO); BSA (Serva, Heidelberg, Germany); gelatin (Merck, Darmstadt, Germany); [125I] (16.2 mCi/μg -1 sodium iodide, Amersham & Buchler, Braunschweig, Germany); goat anti-rabbit IgG-peroxidase and goat anti-mouse IgG-peroxidase (Jackson, Avondale, PA); 3,3-diamino-benzidine-tetrahydrochloride (Beyaz, Bayliss, Germany); O-phenylenediamine dihydrochloride (ODP) (Eastman Kodak, Rochester, N.Y.); nitrocellulose membrane filters (Schleicher & Schüll, Dassel, Germany); RPMI 1640 culture medium and FCS (Gibco, Paisley, Scotland); PVC microtiter plates (DYNATECH, Plochingen, Germany); Titer-Tek immun assay plates (Flow Laboratory, Meckenheim, Germany); Venimmon (Behring Werke, Marburg, Germany).

Production and characterisation of MAb 98/6 against u-PA

For the production of MAb against u-PA, female BALB/c mice were immunised by subcutaneous injection of 50 μg purified low molecular (33 kDa) u-PA dissolved in 100 μl PBS, mixed with the same volume of complete Freud’s adjuvant. The membranes were boosted twice, first by subcutaneous injection of the same amount of antigen mixed with incomplete Freud’s adjuvant, followed by a last intraperitoneal injection of the pure antigen in PBS 3 days prior to the fusion. The fusion was performed as described previously (Moldenhauer et al., 1987). Specificity of hybridomas was tested in an ELISA on purified u-PA vs human t-PA and plasminogen. In brief, proteins were coated to activated ELISA microtiter plates (DYNATECH, 0.3 μg/ml; 100 μl 0.05 M sodium carbonate buffer, pH 9.6/well) overnight at room temperature. After two washing steps with PBS + 0.05% Tween 20, non-specific binding sites were saturated with PBS + 0.02% gelatine for 4 h at 37°C. After vigorous washing with PBS + 0.05% Tween 20, MAB 98/6 supernatant (100 μl well) was given to the plates for 1 h at 37°C followed by washing with PBS + 0.05% Tween 20. Peroxidase-conjugated goat anti-mouse Ig diluted in PBS + 0.05% Tween 20, 100 μl well was added for a further hour at 37°C. After four washing steps, the substrate OPD (1 mg ml−1) dissolved in 0.1 M KH₂PO₄, pH 6.0 and 1 μl H₂O₂ (30% v/v stock solution in H₂O) was added to the assay. The reaction was stopped by addition of 1 N H₂SO₄ and the opitimost and kindly provided by Dr. G.J. Hämmerling, German Cancer Research Center, were of mesothelioma origin. Morphological, genetical, biochemical and chromosomal characteristics of these cell lines have been described in the above cited studies. Histology, morphology and characteristic biochemical markers of cell lines established in our laboratory (H.-H.H.) are listed in Table I. All cell lines were regularly grown in RPMI 1640 medium supplemented with 5% FCS. For assays, serum supplement was reduced to 1% FCS. Reduction of FCS content did not change morphology, proliferation rate and amount of cell-bound u-PA as determined in preceding experiments. In contrast to SCLC cell lines, NSCLC and mesothelioma cell lines grew plastic adherent and were brought into suspension by short treatment with a 0.2% EDTA (w/v) solution in PBS. SCLC cells grew in floating clusters. Single cell suspensions were produced by gently pipetting clusters up and down. All cell lines were screened for the absence of mycoplasts.

CRIA for u-PA determination on cell surface

Monoclonal antibodies and u-PA were [125I]-labelled by the Chloramine T method (Greenwood et al., 1963). In brief, 100 μg of the protein solution in 100 μl PBS was incubated with 1 μCi of Na¹²⁵I and 50 μl Chloramin T (1 mg 1 ml−1 distilled water) for 1 min at room temperature. Reaction was stopped by addition of 50 μl sodium metabisulphite (1 mg Na₂S₂O₄ 1 ml−1 distilled water). The reaction mixture was given immediately over a ion exchange chromatography column (2 ml volume, Dowex 50 W-X8, 200–400 mesh size, 2 column volumes). Fractions of 500 μl were sampled and measured for radioactivity. The peak fraction, was used for the cellular radioimmuno assay (CRIA). The CRIA was performed in flexible polynyl chloride microtiter plates, as described previously (Schwartz et al., 1985). Plates were blocked for nonspecific binding by preincubation with PBS + 0.2% (v/v) gelatine (200 μl well) at 4°C overnight. After emptying, 1 x 10⁶ viable target cells in 50 μl PBS + 0.2% gelatine and 5% (v/v) pooled human immunoglobulins (Venimmon) were incubated with 2 x 10⁶ c.p.m. of [125I]-labelled MAb or [125I]-labelled u-PA in 100 μl PBS + 0.2% gelatine + 5% Venimmon for 1 h at room temperature. The plates were washed four times with PBS + 0.2% gelatine by centrifugation and aspiration of the supernatant. Radioactivity of specifically cell-bound MAb was determined in a gamma-counter. The CRIA was applied in three different test systems:

1. In order to detect specifically u-PA bound MAb, [125I]-labelled MAb 98/6 was applied as described above. As controls, radiolabelled MAb HEA 125 and HD 37 were used.

2. To determine unoccupied binding sites for u-PA, cell lines were incubated with [125I]-labelled, two-chain u-PA as described.

3. For estimation of u-PA binding capacity in case of mesothelioma cell lines, cells were preincubated with 10 μg unlabelled, two-chain u-PA/1 x 10⁶ cells for 1 h at room temperature prior to incubation with [125I]-labelled MAb 98/6.

In order to test for binding specificity of u-PA, representative cell lines of squamous cell carcinoma, large cell carcinoma, SCLC and mesothelioma were incubated with 2 x 10⁶ c.p.m. of [125I]-labelled u-PA in excess (1–10 μg u-PA/1 x 10⁶ cells). Addition of 1 μg unlabelled u-PA abolished binding of 125I-u-PA to background values in all cell lines. In SCLC cell lines competition with unlabelled u-PA had no effect on the residual radioactivity bound. Unrelated proteins such as insulin or thrombin added in the same amounts as unlabelled u-PA did not affect specific binding of 125I-u-PA to the cells.

Estimation of the number of cell surface-expressed u-PA molecules was done by measuring the binding of 125I-labelled MAb 98/6 followed by Scatchard plot analysis (Scatchard, 1949).

Western blot analysis and immunochemical staining

After separation of u-PA on SDS-PAGE, both under reducing and non-reducing conditions, the electrophoretic transfer
| Cell line       | Source                                      | Histology                              | Morphology       | PDT (hours)* | DCC (U mg⁻¹)ᵇ | NSE (ng mg⁻¹)ᶜ | Reference                        |
|----------------|---------------------------------------------|----------------------------------------|------------------|--------------|----------------|----------------|----------------------------------|
| EPLC 32M1      | Xenotransplant of cell line from primary tumour | Squamous cell carcinoma, poorly differentiated | Monolayers, adherent | 16           | <1             | 97             | Bepler et al., 1988              |
| EPLC 65H       | Lymph node metastasis                        | Squamous cell carcinoma, poorly differentiated | Monolayers, adherent | 19           | <1             | 74             | –                                |
| LCLC 97TM1     | Xenotransplant of primary tumour             | Large cell carcinoma                   | Monolayers, adherent | 26           | <1             | 72             | –                                |
| LCLC 103H      | Pleural effusion                             | Large cell carcinoma with giant cells  | Monolayers, adherent | 40           | <1             | 286            | –                                |
| MSTO 211H      | Pleural effusion                             | Mesothelioma, malignant biphasic       | Monolayers, adherent | 20           | <1             | 290            | –                                |
| SCLC 21H       | Pleural effusion                             | Small cell carcinoma, oat cell type    | Clusters, floating | 45           | <1             | 598            | Bepler et al., 1987 a,b          |
| SCLC 22H       | Pericardial effusion                          | Small cell carcinoma, oat cell type    | Clusters, floating | 75           | 300            | 661            | –                                |
| SCLC 24H       | Pleural effusion                             | Small cell carcinoma, oat cell type    | Clusters, floating | 70           | 205            | 343            | –                                |
| SCLC 86M1      | Pleural effusion, Xenotransplant             | Small cell carcinoma, oat cell type    | Clusters, floating | 70           | 4              | 270            | –                                |

*Population doubling time, ᵃL-DOPA decarboxylase, ᵇNeuron-specific enolase. For cell lines SK-LC-LL (derived from a squamous cell carcinoma), SK-LU-1 (derived from a primary, poorly differentiated adenocarcinoma) and CH₂LC (derived from a mesothelioma) no histopathological and histochemical data were available.
of u-PA to nitrocellulose was performed at 5 V cm\(^{-1}\) overnight at 4°C as described (Towbin et al., 1979). Unspecific binding sites were blocked by a solution of 2% BSA in PBS for 1 h at room temperature. Incubation with specific antibodies and second peroxidase-conjugated antibody was carried out in PBS + 1% BSA, each for 1 h at room temperature. After every incubation with antibody solutions, the nitrocellulose was vigorously washed with PBS + 0.05% NP40. Finally, the binding of antibodies was visualised with diaminobenzidine (1 mg ml\(^{-1}\) in 0.05 M Tris/HCl, pH 7.6) with 0.01% \(\text{H}_2\text{O}_2\). The staining reaction was stopped by rinsing the nitrocellulose with 0.05 M Tris/HCl, pH 7.4.

**Results**

**Characterisation of u-PA specific MAb 98/6**

Monoclonal antibody 98/6 specific for u-PA was of IgG1 isotype as determined by an ELISA using subclass-specific goat anti-mouse Ig antibodies. In Western Blot analysis, MAb 98/6 reacted with the 54 kDa two chain form and the 33 kDa single chain form of u-PA under non-reducing conditions and with the 33 kDa but not with the 24 kDa chain of the 54 kDa two chain form under reducing conditions (Figure 1). In immunoprecipitation of lysates from surface radiiodinated cells, MAb 98/6 precipitated a protein which ran in gel electrophoresis under reducing conditions at approx. 50 kDa (data not shown). Therefore, MAb 98/6 most likely also recognises the pro-u-PA from. The MAb 98/6 reacted neither with human t-PA nor with plasminogen as evaluated by ELISA.

**Cell surface expression of endogenous u-PA on human lung tumour cell lines**

Twelve human lung tumour cell lines of different origin, histology and growth characteristics (Table I) were studied for their surface expression of u-PA in a cellular radioimmuno assay (CRIA) using radiolabelled MAb 98/6 specific for u-PA. (Table II). Three groups of lung tumour cell lines could be distinguished by this criterion. NSCLC cell lines of squamous cell/adenocarcinoma origin showed weak reaction with MAb 98/6 (3–5 fold background binding) which was increased after PMA treatment. The two large cell carcinoma cell lines had a much stronger reaction with MAb 98/6 than squamous cell carcinoma cell lines which could also be enhanced by PMA.

All SCLC cell lines and the two cell lines of mesothelioma origin were negative for u-PA surface expression. Binding of MAb 98/6 in the range of 200–600 c.p.m., which occasionally occurred in these cell lines, was considered as unspecific. It was previously shown that these cell lines do not synthesise u-PA (Heidtmann et al., 1989).

To assess the number of u-PA molecules present on the surface of viable cells, we performed Scatchard plot analyses. For example, cell line EPLC 32M1 expressed approx. 3.6 \times 10^3 u-PA molecules/cell under normal cell culture conditions and approx. 1.6 \times 10^3 u-PA molecules/cell after PMA treatment (Figure 2). As expected from CRIA results, cell line LCLC 103H expressed more u-PA molecules than the squamous cell carcinoma cell lines (approx. 1.88 \times 10^4 molecules/cell untreated and approx 1.9 \times 10^5 molecules/cell after treatment with PMA).

The epithelium-specific MAb HEA 125 was applied in the CRIA as positive control MAb for epithelial cells. This MAb had previously been shown to react with NSCLC cell lines and in an even stronger fashion with SCLC cell lines (Moldenhauer et al., 1987). These results could be affirmed in the CRIA performed for this study. In all epithelial cell lines expression of the HEA 125 antigen was unchanged or even reduced after PMA treatment.

**Cell surface binding of exogenous u-PA to human lung tumour cell lines**

The capacity of the cell lines to bind exogenous, radiiodinated two chain (54 kDa) u-PA is given in Table III. In this CRIA, the presence of unoccupied binding sites for u-PA was determined. Squamous/adenocarcinoma and large cell carcinoma cell lines expressed endogenous u-PA at the surface as shown in Table II. Additionally, these cell lines had free binding capacity for u-PA. Both LCLC cell lines showed

---

**Table II** Surface expression of endogenous u-PA on human lung tumour cell lines with and without PMA treatment

| Tumour type | Cell line | - PMA \(^a\) (cpm) | + PMA (cpm) |
|-------------|-----------|-----------------|-------------|
| Squamous cell carcinoma | EPLC 32 M1 | 4,920 ± 20 | 13,210 ± 320 |
| | EPLC 65H | 3,010 ± 10 | 11,930 ± 570 |
| | SK-LC-LL | 1,470 ± 60 | 6,480 ± 170 |
| Adeno carcinoma | SK-LU-1 | 2,110 ± 110 | 6,520 ± 130 |
| Large cell carcinoma | LCLC 97TM1 | 63,890 ± 2,550 | 90,920 ± 7,630 |
| | LCLC 103H | 121,290 ± 13,000 | 163,710 ± 2,030 |
| Mesothelioma | MSTD 211H | 300 ± 260 | 420 ± 130 |
| | CH,LC | 0 | 0 |
| Small cell carcinoma | SCLC 21H | 430 ± 320 | 600 ± 60 |
| | SCLC 324H | 0 | 320 ± 210 |
| | SCLC 86M1 | 0 | 230 ± 180 |

\(^a\) Cells were incubated with and without PMA (5 \times 10^{-5} M) for 3 days.

---

Figure 1: Western blot analysis of MAb 98/6 on purified human u-PA. Human u-PA (54 kDa, two chain) was separated on 12% SDS-PAGE prior to transfer to nitrocellulose. PAGE was run under non-reducing a.e, and reducing conditions b,d,e,f. Specific staining was performed with MAb 98/6 a,b, and a polycional rabbit anti-u-PA serum (produced by one of the authors, G.M.) c,d, recognising both chains of u-PA; an irrelevant MAb (HD20) e, and rabbit pre-immune serum f, were taken as controls.
UROKINASE ON HUMAN LUNG TUMOUR CELL LINES

Table III Binding of 125I-labelled u-PA to human lung tumour cell lines with and without PMA treatment

| Tumour type | Cell line | Binding of 125I-u-PA (cpm) - PMA* | + PMA |
|-------------|-----------|---------------------------------|-------|
| Squamous    | EPLC 32 M1| 13,700 ± 410                      | 480   |
| cell        | EPLC 65H | 11,880 ± 1,520                    | 27,830 ± 350 |
| carcinoma   | SK-LC-LL | 18,390 ± 410                      | 24,000 ± 670 |
| Adenocarcinoma | SK-LU-1 | 13,510 ± 220                      | 17,260 ± 300 |
| Large cell  | LCLC 9T7M | 101,370 ± 1,720                   | 71,950 ± 4,930 |
| carcinoma   | LCLC 103H| 124,300 ± 16,280                  | 60,520 ± 3,140 |
| Mesothelioma| M5STO 21H | 19,330 ± 1,140                    | 21,800 ± 580 |
| Cell lines  | 2CH2L | 28,000 ± 1,020                    | 54,830 ± 3,690 |
| Small cell  | SCLC 21H | 2,000 ± 1,150                     | 3,100 ± 1,150 |
| carcinoma   | SCLC 22H | 0                                | 2,700 ± 670 |
| SCLC 24H    | 0        | 0                                | 0      |
| SCLC 86M1   | 0        | 0                                | 0      |

*Cells were incubated with and without PMA (5 × 10⁻⁹ M) for 3 days. 
+ Standard deviation (s.d.) of triplicates. Presence of u-PA binding sites was determined by using 125I-labelled two chain 54 kDa u-PA. Approximate background values were evaluated by incubating cells with 2 × 10⁶ c.p.m. 125I-u-PA and 1 µg unlabelled u-PA at the same time. These values were subtracted from those of 125I-u-PA binding. This CRIA was carried out three times with essentially identical results.

a much stronger binding of 125I-u-PA than squamous cell carcinoma lines. As an exception, binding of external u-PA was reduced after PMA treatment in these cells. Although two SCLC cell lines showed low binding values of 125I-u-PA in the experiment presented in Table III, we regarded all SCLC cell lines as negative for u-PA binding sites for the following reasons: (i) in kinetic studies SCLC lines did not respond with an increased binding of 125I-u-PA like the other cell lines positive for u-PA binding (Figure 3) (ii) competition experiments with unlabelled u-PA did not result in a concentration-dependent reduction of 125I-u-PA binding. In contrast, cell lines of mesothelioma origin, although deficient to produce u-PA (Heidmann et al., 1989), were able to bind exogenous u-PA in amounts comparable to those of squamous cell carcinoma lines. Also, PMA enhanced binding of u-PA in these cells.

In contrast to the findings of other groups, who investigated the nature of the u-PA receptor, (Plow et al., 1986; Stoppelli et al., 1986) labelled u-PA could not be replaced by unlabelled u-PA (applied in the range of 10⁻⁹ - 10⁻⁰ µg) when unlabelled u-PA was added to the cells after 60 min incubation with 125I-u-PA. This result was observed with squamous cell carcinoma and mesothelioma cell lines, both untreated and treated with PMA. Since binding of u-PA to the cells was irreversible, it did not seem to be mediated by the u-PA receptor described earlier (Stoppelli et al., 1985). We tentatively conclude that surface binding of exogenous, two-chain u-PA occurs via an irreversible, presumably covariant, complex with a yet unknown surface protein. Further biochemical characterisation of this complex, which will be published elsewhere, supports this notion. This irreversible complex formation may also explain why Scatchard plot analysis of exogenous 125I-labelled u-PA binding did not result in a linear function.

In kinetic experiments maximum binding of external u-PA was achieved after a 60 min incubation period at room temperature for NSCLC and mesothelioma cell lines (Figure 3). Estimation of u-PA binding sites on the surface of cell line CH2LC being devoid of endogenous u-PA

Since cell lines of mesothelioma origin were the only ones studied here which did not produce u-PA, but were able to bind exogenous u-PA, we closer examined the capacity of these cells to bind u-PA. For this purpose, CH2LC cells were preincubated with unlabelled u-PA (10 µg/1 × 10⁶ cells) for 1 h at room temperature and then 125I-mAb 98/6 was added in increasing amounts. Scatchard analysis yielded 7.23 × 10⁹ occupied binding sites/cell for untreated cells and 1.96 × 10⁹ occupied binding sites/cell for PMA-treated cells (Figure 4). Direct measurement of u-PA binding sites by incubation of cells with various amounts of radiolabelled u-PA did not result in a reliable linear Scatchard plot.

In competition experiments unlabelled u-PA was simultaneously added in increasing amounts to CH2LC cells together with a constant amount of labelled u-PA. After addition of 0.01 µg unlabelled u-PA/1 × 10⁶ cells, saturation of binding was achieved (Figure 5).
These results are in keeping with and extend previous observations (Heidtmann et al., 1989). In the earlier study we found that NSCLC cell lines could produce u-PA along with other components of the PA system, whereas SCLC and mesothelioma cell lines were deficient in the synthesis of any protein of the PA system. The finding that mesothelioma cell lines are able to bind u-PA despite of their deficiencies for the synthesis of PA may add a new parameter for the differentiation of these lung tumours. It also demonstrates that lung tumours of different origin produce the components of the PA system and proteins of functional context in various combinations which may ensue a different response to signals of the microenvironment. For example by means of free u-PA binding sites, mesothelioma cells could make use of u-PA secreted by other cells. Since SCLC cell lines were deficient of any constituent of the PA system and unresponsive to treatment with PMA or growth factors, the high malignancy of this tumour class may not be correlated to a tumour-associated proteolytic activity of the PA system. It may however well be that other proteinases or proteinases of tumour-infiltrating normal cells play a role in the invasive process of SCLC.

In an earlier study, Markus et al., 1980 investigated human lung tumour tissue for its content of plasminogen activator. No significant correlation was observed between the histopathological types and grades of malignancy of squamous cell carcinoma, adenocarcinoma and anaplastic carcinoma and the overall content of u-PA in these tissues. The u-PA producing cells were not defined in this study. Normal cells present in tumour tissues, as for example macrophages (Neumann & Sorge, 1983) and granulocytes (Granelli-Piperno et al., 1977), are known to produce large amounts of u-PA. Indeed, recently it was reported that, when examining tumour tissue, colon carcinoma cells did not produce m-RNA for u-PA. Increased levels of u-PA-specific m-RNA were however found in interstitial stromal cells at invasive foci. Furthermore, some tumours cells were found to produce m-RNA specific for the u-PA receptor (Pyke et al., 1991). It may well be that tumour cells, deficient of PA production, stimulate normal cells of the environment to increased proteolytic activity. The expression of the u-PA receptor or other, not yet defined binding structures for u-PA, may enable these tumour cells to direct PA activity, present in the microenvironment, to sites of invasive growth. If this were the case, one would expect to find u-PA in close association with tumour cells within tumour tissue. However, immunohistological examination of colon carcinoma tissue, using specific MAb against u-PA, failed to detect u-PA located on or close to the tumour cells (Grundahl-Hansen et al., 1988). Therefore, the function of u-PA binding sites on tumour cells, deficient of the PA system, remains obscure at the moment. It has been reported by several authors that pro-u-PA binds to a specific surface receptor (Stoppelli et al., 1986; Vassalli et al., 1985). The binding of active two-chain u-PA to the cell surface is still a matter of controversy. Although PA activity can be measured on cells, this does not unequivocally prove the binding of active u-PA to specific receptors. Rapid conversion of receptor-bound pro-u-PA to active u-PA may also occur. On the other hand, u-PA has been demonstrated to form irreversible complexes with plasminogen activator inhibitors, as e.g. PAI-1 (Hébert & Baker, 1988) and protease nexin (Howard & Knauer, 1987) which may also be situated on the cell surface via a nexin-binding protein.

NSCLC cell lines had binding sites which were occupied with endogenous u-PA. Since MAB 98/6 does not differentiate between pro-u-PA and active u-PA, surface staining by this antibody may indicate expression of both forms of u-PA and, consequently specific u-PA receptors and other proteins with binding capacity for u-PA. Mesothelioma cells had amounts of binding sites (Figure 1) comparable to those of squamous cell carcinoma cell lines (Figure 2), which additionally expressed endogenous u-PA. It may therefore be that endogenous, active u-PA binds to a type of structure, present on both cell types, which is not involved in

Discussion

In this study a CRIA was employed to determine cell surface expression of endogenous u-PA on various human lung cancer cell lines by using an a-PA specific monoclonal antibody. Binding capacity of these cells for u-PA was measured by applying exogenous, two-chain, active u-PA in the CRIA. The cell lines could be distinguished into three distinct groups by these parameters: (1) squamous cell carcinoma cell lines and – to a much greater extent – large cell carcinoma cell lines expressed u-PA and were also able to bind exogenous u-PA. (2) SCLC cell lines neither expressed nor were able to bind u-PA and (3) mesothelioma cell lines did not express endogenous, but could bind external u-PA.

Figure 5 Competitive binding of unlabelled and 125I-labelled u-PA on CH3LC cells. CH3LC cells (1 x 10⁸) were incubated with 125I-u-PA (2 x 10⁶ c.p.m.) together with increasing amounts of unlabelled u-PA for 1 h at room temperature for the CRIA. Prior to the assay, cells were incubated for 3 days in the absence (○) or presence (▲) of PMA (5 x 10⁻⁴ M).

Figure 4 Scatchard plot analysis of MAb 123I-98/6 binding to CH3LC cells under untreated a, and PMA-treated conditions (5 x 10⁻⁴ M), 3 days b. In order to achieve binding of MAb 98/6, CH3LC cells were preincubated with 10 µg unlabelled u-PA/1 x 10⁶ cells for 1 h at room temperature prior to CRIA. Radiolabelled MAb 98/6 was given in increasing amounts (from 5 x 10⁵ to 3 x 10⁷ c.p.m./1 x 10⁶ cells) for 1 h at room temperature.
binding of endogenous pro-u-PA. NSCLC cell lines had free binding capacity which could be occupied by exogenous u-PA.

Competition of unlabeled u-PA after consecutive addition did not result in a replacement of labeled u-PA. This is in contrast to earlier studies which found reversible binding of pro-u-PA to its specific receptor with a low dissociation rate (Stopelli et al., 1985). Further biochemical analysis of cell-bound exogenous u-PA on lung tumour cells supports our notion that active u-PA forms an irreversible complex with a yet undefined protein (manuscript in preparation).

This study along with our previous ones concerning the PA system of human lung tumour cell lines indicates the possibility that the PA system is differentially expressed in various groups of lung tumours. For a comprehensive evaluation of the functional role of the PA systems, all components of plasminogen activation and inhibition as well as surface binding sites and the influence of growth factors on the tumour system have to be taken into account. Furthermore, to understand in situ tumour-microenvironment interactions, it will be necessary to transfer these insights to the investigation of native tumour samples.

We sincerely thank Anette Merling, Sabine Schmitt and Karin Beisenherz for their excellent technical assistance. This study was supported in part by a grant from the Tumourzentrum Heidelberg/Mannheim and by the SFB 215 of the Deutsche Forschungsgemeinschaft.

References

BAKER, J.B., LOW, D.A., SIMMER, R.L. & CUNNINGHAM, D.D. (1980). Protease-Nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell, 21, 37.

BEPLER, G., JAQUES, G., KOEHLER, A., GROPP, C. & HAVEMANN, K. (1987a). Markers and characteristics of human SCLC cell lines. Cancer, Clin. Oncol., 113, 235.

BEPLER, G., JAQUES, G., NEUMANN, K., AUMULLER, G., GROPP, C. & HAVEMANN, K. (1987b). Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines. J. Cancer Res. Clin. Oncol., 113, 31.

BEPLER, G., KOEHLER, A., KIEFER, P. & 5 others (1988). Characterization of the state of differentiation of six newly established non-small-cell lung cancer cell lines. Differentiation, 37, 158.

CUBELLIS, M.V., WUN, T.-C. & BLASI, F. (1990). Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J, 9, 1079.

CWIKEL, B.J., BAROUSKI-MILLER, P.A., COLEMAN, P.L. & GELEHRER, T.D. (1984). Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells. J. Biol. Chem., 259, 6847.

DANO, K., ANDREASEN, P.A., GRONDAHL-HANSEN, J., KRISTENSEN, P., NIELSEN, L.S. & SKRIVER, L. (1986). Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139.

EATON, D.L. & BAKER, J.B. (1983). Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiafactor/antiplasmin. J. Biol. Chem., 258, 97.

FOGH, J. & TREMPE, G. (1975). New human cell lines. In Human Tumour Cells In Vitro, Fogh, J. (ed.) p. 115. Plenum Press, New York.

GAZZARD, A.F., CARNEY, D.N., GUCCION, J.G. & BAYLIN, S.B. (1981). Small cell carcinoma of the lung: cellular origin and relationship to other pulmonary tumours. In Small Cell Lung Cancer, Greco, F.A., Oldham, R.K. & Bunn, P.A. (eds) p. 145. Greune and Stratton, New York.

GENTON, C., KRUTHOFF, E.K.O.R. & SCHLEUNIG, W.D. (1987). Phorbol ester induces biosynthesis of glycosylated and non-glycosylated plasminogen-activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U937 lymphoma cells. J. Cell. Biol., 104, 705.

GRANELLIPPIERNO, A., VASSALLI, J.-D. & REICH, E. (1977). Secretion of plasminogen activator by human polymorphonuclear leukocytes. Modulation by glucocorticoids and other effectors. J. Exp. Med., 146, 1693.

GRIDERWOOD, F.C., HUNTER, W.M. & GLOVER, J.S. (1963). The preparation of 125I-labelled human growth hormone of high specific radioactivity. Biochem. J., 89, 114.

GRONDAHL-HANSEN, J., RALFKAIER, E., KIRKEBY, L.T., KRISTENSEN, P., LUND, L.R. & DANO, K. (1991). Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinoma of the colon in man. Am. J. Pathol., 138, 111.

HEBERT, C.A. & BAKER, J.B. (1988). Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of vimentin and the PA system with vimentin, J. Cell Biol., 106, 1241.

HEIDTMANN, H.-H., HOFMANN, M., JACOB, E., ERBL, C., HAVEMANN, K. & SCHWARTZ-ALBIEZ, R. (1989). Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumours. Cancer Res., 49, 6980.

HOWARD, E.W. & KNAUER, D.J. (1987). Characterization of the receptor for protease nexin-I: protease complexes on human fibroblasts. J. Cell. Physiol., 131, 276.